Lundbeck to utilize fast-track status in Alzheimer's drug dialog with FDA

Lundbeck CEO Deborah Dunsire announces that preparations for an FDA application are underway, and the US is not the only market the company is eyeing for its agitation candidate brexpiprazol. Promising data on the drug was publicized on Monday morning.

Deborah Dunsire, CEO, Lundbeck | Photo: Gregers Tycho/ERH

Pharmaceutical company Lundbeck is naturally very pleased with the positive topline data the firm and its partner Otsuka Pharmaceuticals released for its candidate brexpiprazol on Monday morning.

Lundbeck has already started to work on a registration application to the US Food and Drug Administration (FDA) which is expected to be submitted later this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs